Skip to main content
OpenTrials
Completed

NCT Number: NCT03761615

Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy

The overall goal of this study is to enroll pregnant women with type 1 diabetes and follow their glycemic outcomes prospectively throughout pregnancy and into the post-partum period. The investigators anticipate that when compared to subjects using an Artificial pancreas system (AP) as part of a future protocol, this comparator group of subjects undergoing usual care will exhibit less time in target continuous glucose monitoring (CGM) glucose range defined as 63-140 mg/dL and an increased duration of hypoglycemia with CGM glucose <63 mg/dL.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Sansum Diabetes Research Institute, Santa Barbara, California, United States

Loading trial locations.

About this study

This is an observational study. Data collected will include records of continuous glucose monitoring (CGM) based glucose, insulin delivery, self-monitoring of blood glucose (SMBG), and maternal and fetal outcomes from pregnant women with type 1 diabetes. These data will be used to: (1) develop and refine algorithms for an AP system tailored to the needs of pregnant women with type 1 diabetes, (2) to serve as a comparator group for concurrent AP protocols, (3) describe Dexcom G6 CGM data throughout the pregnancy, and (4) describe insulin changes which occur in pregnancy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis, based on investigator assessment, of T1D for at least one year and using insulin for at least 1 year.
  • Criteria for documented hyperglycemia (at least 1 must be met):
  • Fasting glucose ≥126 mg/dL
  • Two-hour OGTT glucose ≥200 mg/dL
  • HbA1c ≥6.5% documented
  • Random glucose ≥200 mg/dL with symptoms
  • No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with T1D
  • Criteria for requiring insulin at diagnosis (1 must be met):
  • Participant required insulin at diagnosis and continually thereafter.
  • Participant did not start insulin at diagnosis but upon investigator review likely needed insulin (significant hyperglycemia that did not respond to oral agents) and did require insulin eventually and used continually.
  • Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies - consistent with latent autoimmune diabetes in adults (LADA) and did require insulin eventually and used continually.
  • Currently using an insulin pump for diabetes management
  • Currently using or willing to use an insulin-to-carbohydrate ratio to calculate meal bolus sizes
  • Willing to change insulin infusion site at least every 3 days.
  • Confirmed pregnancy
  • Current gestational age <17 weeks
  • Age 18-40 years
  • HbA1c <10.0%
  • Demonstration of proper mental status and cognition for the study
  • Ability to access the internet and upload CGM data remotely if needed
  • An understanding of and willingness to follow the protocol and sign the informed consent

Exclusion criteria

  • 670 G users in Auto mode
  • Current gestational age ≥17 weeks
  • Cystic fibrosis
  • A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:
  • Inpatient psychiatric treatment in the past 6 months
  • Abnormal renal function test results (calculated GFR <60 mL/min/1.73m2); testing required for subjects with diabetes duration of greater than 5 years post onset of puberty
  • Active gastroparesis
  • Abuse of alcohol or recreational drugs
  • Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis)
  • Uncontrolled arterial hypertension (Resting diastolic blood pressure >95mmHg and/or systolic blood pressure >160 mmHg) at the time of screening
  • Chronic oral steroid use
  • A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol

Treatment and study plan

DEXCOM G6 CGM

Device

All women in the study will be given Dexcom G6 CGM and a study glucometer.

Primary outcomes

  1. Percentage of Time in Range Glucose Levels 63-140 mg/dL as Determined by CGM

    Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum

    Time in range defined as 63-140 mg/dL as determined by CGM analysis

Secondary outcomes

  1. Percentage of Percentage of Time Spent Below Target Glucose (<63 mg/dL) as Determined by CGM

    Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum

    Time spent below target cgm glucose range defined as glucose <63 mg/dL

  2. Percentage of Time Spent Above Target Glucose Range (> 140 mg/dL) as Determined by CGM

    Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum

    Time spent above target cgm glucose range defined as >140 mg/dL

  3. Episodes of Clinically Significant Hyperglycemia

    Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum

    Episodes of clinically significant hyperglycemia with CGM glucose >180 mg/dL

  4. Total Daily Insulin Requirements Over Last 2 Weeks of Third Trimester

    Time frame: 2 weeks

    Total daily insulin requirements (units/kg/day) over last 2 weeks of third trimester

  5. Basal Insulin Requirements Over Last 2 Weeks of Third Trimester

    Time frame: 2 weeks

    Basal daily insulin requirements (units/kg/day) over last 2 weeks of third trimester

  6. Carbohydrate Consumption Over Last 2 Weeks of Third Trimester

    Time frame: 2 weeks

    Carbohydrate consumption (g/(kg*day)) over last 2 weeks of third trimester

Other outcomes

  1. Ketoacidosis

    Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum

    Episodes of ketoacidosis requiring emergency room or hospital admission

  2. Maternal Complications

    Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum

    Maternal complications including preeclampsia, pregnancy induced hypertension and polyhydramnios

  3. Gestational Weight Gain

    Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum

    Gestational weight gain each week

  4. Gestational Age at Delivery

    Time frame: Immediately at birth

    Gestational age at delivery (Weeks)

  5. Birth Weight of Baby

    Time frame: Immediately at birth

    Birth weight of baby (kg)

  6. LGA

    Time frame: Immediately at birth

    Number of Large for Gestational Age based on WHO criteria at time of delivery

  7. Preterm Birth

    Time frame: Immediately at birth

    Number of infants born late preterm birth (at 34-37 weeks)

  8. Neonatal NICU Stay

    Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum

    Number of infants requiring neonatal NICU stay

  9. Cesarean Delivery

    Time frame: Immediately at birth

    Number of participants that underwent primary cesarean section for delivery

Sponsors and collaborators

Lead sponsor

Sansum Diabetes Research Institute

Other

Collaborators

  • Harvard University
  • Icahn School of Medicine at Mount Sinai
  • Mayo Clinic

Registry information

Official study title

Observational Study of Patient Important Outcomes in Pregnant Patients With Type 1 Diabetes Mellitus on Insulin Pump

Acronym: LOIS-P

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Dec 3, 2018
Registry last updated
Apr 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.